Anika Therapeutics (NSDQ:ANIK) said yesterday that regulatory authorities in Australia approved the company’s single injection viscosupplement, Monovisc, for the treatment of pain associated with osteoarthritis of the synovial joints. This latest regulatory win means that Monovisc is commercially available in more than twenty countries, including the U.S. and Canada. The Bedford, Mass.-based company said it plans […]
Anika Therapeutics Inc.
Anika Therapeutics touts Hyalofast scaffold, stem cell combo
Anika Therapeutics (NSDQ:ANIK) touted data today from a study evaluating the use of its Hyalofast biodegradable, hyaluronic acid-based scaffold in combination with autologous adult mesenchymal stem cell therapy for cartilage lesions in the knee. The study, which was published in Knee Surgery Sports Traumatology Arthroscopy, showed that the treatment was equally effective among patients, regardless of age. […]
Anika names medtech veteran as new president | Personnel Moves – July 31, 2017
Anika Therapeutics (NSDQ:ANIK) last week named medtech veteran Joseph Darling as president, taking over the role from CEO Charles Sherwood. The chief exec plans to stay in the corner office as he transitions the role of president to Darling. Previously, Darling worked as an executive in privately-held orthopedic companies. He has also held senior level executive […]
Anika tops EPS estimate by 32 cents in Q2
Shares in Anika Therapeutics (NSDQ:ANIK) rose today after the orthopedics medicine company topped expectations on Wall Street with its second quarter results. The Bedford, Mass.-based company posted profits of $11.4 million, or 78¢ per share, on sales of $33.5 million for the 3 months ended June 30, for bottom-line growth of 32% on sales growth of 26% […]
India approves Anika’s Monovisc osteoarthritis treatment
Anika Therapeutics (NSDQ:ANIK) said today that regulatory authorities in India approved its single injection viscosupplement, Monovisc, as a therapy for pain associated with osteoarthritis in synovial joints. The Bedford, Mass.-based company’s product is already available in the U.S. Canada and Europe. Anika said it hopes to expand into Australia, New Zealand and other international markets in the […]
Anika inks $350k settlement with former CMO Mascioli, hits $5m milestone
Anika Therapeutics (NSDQ:ANIK) said last week that it agreed to pay former chief medical officer Dr. Stephen Mascioli $350,000 “for all alleged damages and attorneys’ fees.” In return, Mascioli agreed not to pursue legal action against the Bedford, Mass.-based company. Mascioli departed from Anika in January this year, after spending less than a year there. Get […]
Anika launches late-stage supplemental Cingal study
Anika Therapeutics (NSDQ:ANIK) said yesterday that it enrolled the 1st patient in a supplemental Phase III efficacy and safety trial of its Cingal hyaluronic acid-corticosteroid combination viscosupplement. The Bedford, Mass.-bsaed company is evaluating Cingal as a treatment for osteoarthritis-related knee pain. Get the full story at our sister site, Drug Delivery Business News.
Anika onshores manufacturing capabilities with new Bedford facility
Anika Therapeutics (NSDQ:ANIK) opened a new global manufacturing facility today, on the same day that it celebrated the 25th anniversary of its Bedford, Mass.-based headquarters. Anika’s manufacturing operations were previously split between its U.S. headquarters and an Italy-based contract manufacturer. But in a move to onshore manufacturing to the U.S., the company said it hopes […]
Anika touts Phase III data for Cingal knee therapy
Anika Therapeutics (NSDQ:ANIK) touted data today from a Phase III trial for its Cingal hyaluronic acid-corticosteroid combination viscosupplement as a treatment for osteoarthritis-related knee pain. The data showed that treatment with Cingal yielded better immediate and short-term pain relief compared to hyaluronic acid alone and better pain and stiffness relief through 26 weeks compared to saline. […]
Anika misses Q1 earnings by a penny
Shares in Anika Therapeutics (NSDQ:ANIK) fell today after the orthopedics company missed expectations on Wall Street with its 1st quarter results. The Bedford, Mass.-based company posted profits of $5.5 million, or 37¢ per share, on sales of $23.4 million for the 3 months ended March 31, for bottom-line loss of -20.3% on sales growth of 4.9% compared […]
Anika beats Q4 earnings, revenue estimates
Shares in Anika Therapeutics (NSDQ:ANIK) fell today, even though the orthopedic medicines company beat expectations on Wall Street with its 4th quarter results. The Bedford, Mass.-based company posted profits of $8.1 million, or 54¢ per share, on sales of $28.7 million for the 3 months ended Dec. 31, for bottom-line loss of -26% on sales loss of -7% compared with […]
